Patients’ Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)
People with migraine describe reluctance in seeking health care, and misunderstandings seem common especially in the beginning of their migraine journey. Graphical abstract available for this article.
Authors
- Elizabeth K. Seng (ORCID: https://orcid.org/0000-0002-8938-4949)
- Hayley Karn (ORCID: https://orcid.org/0009-0009-6383-9544)
- William R. Lenderking
- Gilwan Kim (ORCID: https://orcid.org/0000-0003-1991-6644)
- Margaret Hoyt (ORCID: https://orcid.org/0000-0002-9486-2095)
- Michael H. Ossipov (ORCID: https://orcid.org/0000-0001-5028-0539)
- Maurice Vincent (ORCID: https://orcid.org/0000-0001-5855-6069)
- Lars Viktrup (ORCID: https://orcid.org/0000-0002-8739-0544)
- Christian Lampl (ORCID: https://orcid.org/0000-0003-4340-3486)
- Dustin Ruff
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Albert Einstein College of Medicine (US)
- University of North Carolina Wilmington (US)
- Eli Lilly (United States) (US)
- Convent Hospital of the Brothers of Saint John of God (AT)
Publication Details
- Journal
- Pain and Therapy
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1007/s40122-024-00652-z
- Citations
- 8
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.08
Funders
- Eli Lilly and Company